ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Epstein-Barr virus (EBV)"

  • 2021 American Transplant Congress

    Overall Survival by Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant

    S. Prockop1, L. Gamelin2, R. Dinavahi2, Y. Sun2, N. Guzman-Becerra2, H. Parmar2

    1Memorial Sloan Kettering Cancer Center, New York, NY, 2Atara Biotherapeutics, South San Francisco, CA

    *Purpose: Tabelecleucel is an investigational, off-the-shelf, allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy being studied in patients (pts) with serious EBV-driven diseases, including post-transplant lymphoproliferative disease…
  • 2021 American Transplant Congress

    T-Cell Exhaustion in EBV DNAemic Solid Organ Transplant Recipients

    S. Kothari, T. Ku, D. Kumar, A. Humar, V. H. Ferreira

    Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada

    *Purpose: In transplant recipients, disease severity after infection with Epstein-Barr virus (EBV) may range from asymptomatic DNAemia to PTLD. Host factors likely play a key…
  • 2020 American Transplant Congress

    Long-Term Safety in Epstein-Barr Virus (EBV)-Seropositive Kidney-Only Transplant Recipients Treated with Belatacept (BELA) in Clinical Practice: Final Study Results from the ENLiST Registry

    C. Larsen1, F. Vincenti2, T. Kou3, C. Shadur4, B. Bresnahan5, S. Jordan6, E. S. Woodle7, N. Goes8, J. Vella9, D. Wojciechowski10, M. Polinsky3, A. Gomez-Caminero3

    1Emory University Transplant Center, Atlanta, GA, 2UCSF Transplant Center, San Francisco, CA, 3Bristol-Myers Squibb, Princeton, NJ, 4Iowa Kidney Physicians, Des Moines, IA, 5Medical College of Wisconsin, Milwaukee, WI, 6Cedars-Sinai Medical Center, Los Angeles, CA, 7University of Cincinnati, Cincinnati, OH, 8Kaiser Permanente, San Francisco, CA, 9Maine Nephrology Associates, PA, Portland, ME, 10University Hospital Kidney and Liver Transplant Clinic, Dallas, TX

    *Purpose: BELA, a selective T-cell costimulation blocker, is approved for the prophylaxis of organ rejection in EBV-seropositive adult kidney transplant recipients. In phase 3 BENEFIT…
  • 2020 American Transplant Congress

    Lifetime Survival Estimates Following Solid Organ Transplantation in the United States

    C. Graham1, M. Skeans2, Y. Ahn2, C. Watson3, A. Barlev4

    1RTI Health Solutions, Research Triangle Park, NC, 2Chronic Disease Research Group, Minneapolis, MN, 3Atara Biotherapeutics, South San Francisco, CA, 4Atara Biotherapeutics, Thousand Oaks, CA

    *Purpose: The Scientific Registry of Transplant Recipients (SRTR) contains detailed patient and graft survival data for all solid organ transplants (SOT) in the United States…
  • 2020 American Transplant Congress

    CMV, EBV and BKV Viremia Rate Varied Depending on the Timing of Conversion to Belatacept (BLT)- from Calcineurin Inhibitor (CNI)-Based Immunosuppression and HLA-Sensitization (HS) Status in Kidney Transplant Patients (KTx Pts)

    B. Shin, N. Ammerman, A. Vo, S. C. Jordan, M. Toyoda, S. Sethi

    Cedars-Sinai Medical Center, Los Angeles, CA

    *Purpose: Viral infections (VI) represent significant morbidity and mortality factors for KTx Pts. We previously showed more VI in BLT-treated Pts compared with CNI Pts…
  • 2020 American Transplant Congress

    Epstein-Barr Virus-Specific Cytotoxic T Lymphocyte Precursors (EBV-CTLp) after Tab-cel Correlates with Response & Survival in Rituximab Relapsing or Refractory Ebv+ Posttransplant Lymphoproliferative Disease (PTLD)

    R. Shen1, N. Guzman-Becerra1, Y. Sun1, F. Forozan1, S. Prockop2, E. Doubrovina2, R. O'Reilly2, X. Li1, M. Hiremath3, L. Gamelin1, W. Navarro1, B. Aftab1

    1Atara Biotherapeutics, Thousand Oaks, CA, 2Memorial Sloan Kettering Cancer Center, New York, NY, 3Atara Biotherapeutics, South San Francisco, CA

    *Purpose: EBV+ PTLD is often a fatal disease. Tab-cel is an investigational off-the-shelf, allogeneic T-cell immunotherapy specific for EBV antigens. Functional in vivo expansion approximated…
  • 2020 American Transplant Congress

    Epidemiology of EBV Infection and EBV Load Kinetics after Pediatric Living Donor Liver Transplantation

    M. Yamada, A. Fukuda, M. Ogura, S. Shimizu, Y. Ishikawa, F. Kawano, H. Uchida, M. Takeda, Y. Yanagi, S. Sakamoto, M. Kasahara, K. Imadome

    National Center for Child Health and Development, Tokyo, Japan

    *Purpose: Epstein-Barr virus (EBV) is a ubiquitous virus that infects more than 90% of adult population worldwide. EBV infection after pediatric liver transplantation (LT) accounts…
  • 2020 American Transplant Congress

    Transplant Monitoring and PTLD Detection with B Cell Receptor Repertoire Analysis in a Large Prospective Pediatric Cohort

    K. Jackson1, O. Martinez2, S. Krams2, M. Robien3, M. Lapasaran2, B. Armstrong4, C. Twist5, K. Weinberg6, D. Gratzinger1, B. Tam1, M. Sever4, M. Brown3, D. Bernstein6, C. Esquivel2, S. D. Boyd1

    1Department of Pathology, Stanford Univ School of Med, Stanford, CA, 2Department of Surgery/Division of Abdominal Transplantation, Stanford Univ School of Med, Stanford, CA, 3NIAID, NIH, Bethesda, MD, 4Rho, Chapel Hill, NC, 5Roswell Park, Buffalo, NY, 6Department of Pediatrics, Stanford Univ School of Med, Stanford, CA

    *Purpose: Post-transplant lymphoproliferative disorder (PTLD) remains a serious problem in the pediatric transplant population. The Clinical Trials of Organ Transplantation in Children (CTOT-C)-06 is a…
  • 2020 American Transplant Congress

    Patterns of Belatacept Use and Risk of Post-Transplant Lymphoproliferative Disorder (PTLD) in US Kidney Transplant Recipients – Analysis of Organ Procurement and Transplantation Network (OPTN) Database

    W. S. Cherikh1, T. Kou2, J. Foutz1, A. Gomez-Caminero2

    1United Network for Organ Sharing (UNOS), Richmond, VA, 2Bristol-Myers Squibb, Princeton, NJ

    *Purpose: Belatacept, a selective T-cell costimulation blocker, was approved in 2011 for the prophylaxis of organ rejection in Epstein-Barr virus (EBV)-seropositive kidney transplant recipients. PTLD…
  • 2020 American Transplant Congress

    Long-Term Outcomes of Patients with Epstein-barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ Transplant or Allogeneic Hematopoietic Cell Transplant Treated with Tabelecleucel in an Expanded Access Program Study

    S. Prockop1, R. Reshaf2, D. Tsai3, N. Bunin4, R. Abu-Arja5, K. Mahadeo6, W. Weng7, K. Van Besien8, D. Loeb9, S. Dwivedy Nasta10, E. Nemecek11, M. Hiremath12, S. Yue12, Y. Sun12, W. Navarro12, S. Nikiforow13

    1Memorial Sloan Kettering Cancer Center, New York, NY, 2Columbia University Irving Medical Center, New York, NY, 3Loxo Oncology, Stamford, CT, 4The Children's Hospital of Philadelphia, Philadelphia, PA, 5Nationwide Children's Hospital, Columbus, OH, 6MD Anderson Cancer Center, Houston, TX, 7Stanford University School of Medicine, California, CA, 8Weill Cornell Medical College, New York, NY, 9Children's Hospital at Montefiore, Bronx, NY, 10University of Pennsylvania, Philadelphia, PA, 11Oregon Health & Science University, Portland, OR, 12Atara Biotherapeutics, New York, NY, 13Dana Farber Cancer Institute, Boston, MA

    *Purpose: There is a need for effective, well‑tolerated therapies in pts who develop Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after solid organ (SOT) or…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 10
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences